Inhibrx Biosciences (INBX) EPS (Basic) (2023 - 2026)
Inhibrx Biosciences (INBX) posted quarterly EPS (Basic) of -$2.12 for Q4 2025, up 34.44% year-over-year from -$1.58 in Q4 2024, and up 6.92% quarter-over-quarter from -$2.28 in Q3 2025.
Powered by 
Analysis
Inhibrx Biosciences (INBX) EPS (Basic) (2023 - 2026) Analysis & Trends
Inhibrx Biosciences (INBX) has reported EPS (Basic) for 3 consecutive years, with -$2.12 the latest figure, recorded in Q4 2025.
- In Q4 2025, EPS (Basic) rose 34.44% year-over-year to -$2.12; the TTM figure through Dec 2025 stood at -$9.04 (down 107.93% YoY), while the FY2025 annual figure was -$9.04, down 107.93% from the prior year.
- EPS (Basic) rose to -$2.12 in Q4 2025 per INBX's latest filing, from -$2.28 in the prior quarter.
- Across five years, EPS (Basic) topped out at $127.1 in Q2 2024 and bottomed at -$7.81 in Q4 2023.
- Historically, EPS (Basic) has averaged $8.15 across 3 years, with a median of -$2.84 in 2024.
- Annual changes were most pronounced in 2024 — EPS (Basic) soared 3047.25% — and 2025, when it slumped 101.46%.
- Inhibrx Biosciences' EPS (Basic) stood at -$7.81 in 2023, then soared by 58.57% to -$3.23 in 2024, then surged by 34.44% to -$2.12 in 2025.
- Business Quant data shows INBX's EPS (Basic) at -$2.12 in Q4 2025, -$2.28 in Q3 2025, and -$1.85 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.27 Bn | 131.42 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.55 Bn | 77.56 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 63.45 Bn | 58.27 Bn | 1.37 Bn | 7.70 |
| 4 | Moderna | 57.73 Bn | 52.59 Bn | 52.00 Mn | -1.96 |
| 5 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - | -3.06 |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 2.12 |
| 7 | Alnylam Pharmaceuticals | 35.14 Bn | 31.84 Bn | 992.69 Mn | 1.23 |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 0.18 |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -0.06 |
| 10 | Inhibrx Biosciences | 1.92 Bn | 1.92 Bn | - | -2.34 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -2.34 |
| Dec 31, 2025 | -2.12 |
| Sep 30, 2025 | -2.28 |
| Jun 30, 2025 | -1.85 |
| Mar 31, 2025 | -2.80 |
| Dec 31, 2024 | -3.23 |
| Sep 30, 2024 | -2.84 |
| Jun 30, 2024 | 127.10 |
| Mar 31, 2024 | -5.77 |
| Dec 31, 2023 | -7.81 |
| Sep 30, 2023 | -4.39 |
| Jun 30, 2023 | -4.31 |